medigraphic.com

2004, Número s2

<< Anterior Siguiente >>

Arch Cardiol Mex 2004; 74 (s2)


Tratamiento de la placa rota complicada

Gaxiola LE

Idioma: Español
Referencias bibliográficas: 24
Paginas: 248-256
Archivo PDF: 100.64 Kb.


RESUMEN

La ruptura de una placa ateroesclerosa puede seguir curso asintomático con reparación e incremento del grado de estenosis o producir síndromes coronarios agudos: angina inestable/infarto sin elevación del segmento ST o infarto agudo del miocardio. En angina inestable, de acuerdo a la estratificación de riesgo, la terapia debe incluir: 1) fármacos anti-isquemia miocárdica, 2) anticoagulantes y antiplaquetarios orales y/o intravenosos, 3) terapia invasiva. En el infarto agudo del miocardio, el tratamiento de reperfusión puede ser farmacológico, mecánico o la asociación de ambos. El objetivo es disolver el trombo, evitar embolismo distal y obtener flujo epicárdico y tisular adecuado.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Rioufol G, Finet G, Ginon I, André-Fouët X, Rossi R, Vialle E, et al: Multiple atheroesclerotic plaque ruptures in acute coronary syndrome. A three-vessel intravascular ultrasound study. Circulation 2002; 106: 804-808.

  2. O´Malley PG, Taylor AJ, Jackson JL, Doherty TM, Detrano RC: Prognostic value of coronary electron-beam computed tomography for coronary heart disease events in asymptomatic populations. Am J Cardiol 2000; 85(8): 945-48.

  3. Burkle AP, Kolodgie FD, Farb A, Weber DK, Malcolm GT, Smialek J, et al: Healed plaque ruptures and sudden coronary death: evidence that subclinical rupture has a role in plaque progression. Circulation 2001; 103(7): 934-40.

  4. Libby P, Ridker PM, Maseri A: Inflammation and Atherosclerosis. Circulation 2002; 105: 1135-1143.

  5. Braunwald E: Unstable angina. An etiologic approach to management. Circulation 1998; 98: 2219-2222.

  6. Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, et al: ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients with unstable angina). 2002. Available at: http://www.acc.org/clinical/guidelines/unstable.pdf

  7. Boersma E, Pieper KS, Steyerberg EW, et al: Predictors of outcome in patients with acute coronary syndromes without persistent ST segment elevation: Results from an internacional trial of 9461 patients. The PURSUIT Investigators. Circulation 2000; 101: 2557-67.

  8. Antman EM, Cohen M, Bermink PJLM, et al: The TIMI risk store for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA 2000; 284-835-42.

  9. Bertrand ME, Simoons ML, Fox KAA: Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Task Force of the European Society of Cardiology. Eur Heart J 2002; 23: 1809-40.

  10. Budaj A, Yusuf S, Metha SR, Fox KAA, Tognoni G, Zhao F, for the Clopidogrel in Unstable Angina to prevent Recurrent Events (CURE) Trial Investigators: Benefit of clopidogrel in patients with acute coronary syndromes without ST-segment elevation in various risk groups. Circulation 2002; 106: 1622-26.

  11. Metha SR, Yusuf S, Peters RJG, Bertrand ME, Lewis BS for the Clopidogrel in Unstable Angina to prevent Recurrent Events (CURE) Trial Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358: 527-33.

  12. Boersma E, Akkerhuis M, Théroux P, Califf RM, Topol EJ, Simoons ML: Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes. Early benefit during medical treatment only, with additional protection during percutaneous coronary intervention. Circulation 1999; 100: 2045-2048.

  13. Simoons ML: Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary reavscularization: the GUSTO IV-ACS randomized trial. Lancet 2001; 357: 1915-24.

  14. Antman EM, Cohen M, radley D, et al: Assessment of the treatment effect of enoxparin for unstable angina/non-Q-wave myocardial infarction: TIMI 11B ESSENCE meta-analysis. Circulation 1999; 100: 1602-08.

  15. Cannon CP, Turpie AGG: Unstable angina and non-ST-elevation myocardial infarction. Initial antithrombotic and early invasive strategy. Circulation 2003; 107: 2640-2645.

  16. Cannon CP, Weintraub WS, Demopoulos LA, Vicari R, Frey MJ, Lakkis N, for the TSACTICS-Thrombolysis in Myocardial Infarction 18 Investigators. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001; 344: 1879-87.

  17. Fibrinolytic Therapy Trialists´(FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocadial infarction: collaborative overview of early mortality and major morbidity results of all randomized trials of more than 1000 patients. Lancet 1994; 343: 311-32.

  18. Lee KL, Woodlief LH, Topol EJ, Weaver WD, Betriu A, Col J, for the GUSTO-I Investigators. Predictor of 30-day mortality in the era of reperfusion for acute myocardial infarction. Circulation 1995; 91: 1659-68.

  19. de Lemos JA, Antman EM, Gibson CM, McCabe CH, Giugliano RP, Murphy SA, et al: Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction: observations from the TIMI 14 trial. Circulation 2000; 101: 239-43.

  20. The GUSTO V Investigators. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: The GUSTO V randomised trial. Lancet 2001; 357: 1905-14.

  21. Weaver WD, Simes RJ, Ellis SG, et al: Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction. A quantitative review. JAMA 1997; 278: 2093-2098.

  22. Keeley EC, Boura JA, Grines CL: Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003; 361: 13-20).

  23. Stone GW, Grines CL, Cox DA, for the CADILLAC Investigators. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002;346:957-66.

  24. Brener SJ, Barr LA, Burchenal JFB, et al: Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. Circulation 1998; 98: 734-741.




2020     |     www.medigraphic.com